कंपनी का अवलोकन
Bausch Health Companies Inc. operates as a diversified entity within the healthcare sector, specifically functioning as a drug manufacturer focused on specialty and generic pharmaceuticals alongside medical device production. The company develops, manufactures, and markets a comprehensive range of products primarily serving therapeutic areas such as gastroenterology, hepatology, neurology, dermatology, as well as generic pharmaceuticals, over-the-counter products, and aesthetics. In terms of scale, the organization employs approximately 20,300 individuals globally and holds a market capitalization of $2.01 billion with an annual revenue of $10.27 billion. These valuation and revenue figures indicate that while the company maintains a significant operational footprint and generates substantial top-line income, its market cap relative to its revenue suggests a valuation structure that prioritizes cash flow and asset value over traditional market premium multiples often seen in large-cap peers.
वित्तीय स्वास्थ्य
The company reported a trailing twelve-month revenue of $10.27 billion, with a corresponding net income of $157.00 million and an EBITDA of $3.40 billion. The substantial disparity between the $10.27 billion in revenue and the $157.00 million in net income reveals a significant cost structure where operating expenses, including cost of goods sold, general and administrative costs, and taxes, consume the majority of top-line proceeds before reaching the bottom line. Despite the lower net income, the EBITDA of $3.40 billion demonstrates robust underlying operational cash generation capability before interest, taxes, depreciation, and amortization. The company generated free cash flow of $1.09 billion, which provides a critical buffer for financial flexibility, allowing for potential debt repayment, share buybacks, or capital expenditures without relying solely on external financing. Profitability efficiency is highlighted by a gross margin of 70.7%, an operating margin of 25.8%, and a profit margin of 1.5%; the high gross margin indicates strong pricing power or low production costs relative to sales, while the lower profit margin reflects the heavy burden of operational expenses and interest obligations. Liquidity and solvency metrics show a cash balance of $1.31 billion against total debt of $21.08 billion, resulting in a debt-to-equity ratio of 5591.25, which indicates a highly leveraged balance sheet structure rather than a conservative one. Short-term liquidity is supported by a current ratio of 1.47, suggesting the company possesses sufficient current assets to cover its short-term liabilities. Return metrics include a Return on Equity of 436.4% and a Return on Assets of 5.2%, where the elevated ROE is mathematically driven by the high leverage and negative price-to-book ratio, while ROA reflects the efficiency of asset utilization in generating profit relative to the total asset base.
मूल्यांकन आकलन
The trailing twelve-month P/E ratio stands at 12.83, while the forward P/E is significantly lower at 1.34, implying that the market prices current earnings much higher than expected future earnings or that future earnings estimates are drastically lower than current performance levels. The price-to-book ratio is listed at -3.61, which indicates that the company's market capitalization is negative relative to its book value, a scenario often associated with high leverage or specific accounting treatments regarding intangible assets and goodwill rather than a traditional market premium over tangible book value. Alternative valuation metrics include a price-to-sales ratio of 0.20 and an EV/EBITDA of 6.68, suggesting that the market values the company at a fraction of its sales revenue and places a low multiple on its earnings before interest, taxes, depreciation, and amortization relative to enterprise value. The stock's price range over the last 52 weeks has fluctuated between a high of $8.69 and a low of $4.25, providing a historical volatility context for the current trading price. The company exhibits a beta of 0.40, indicating that its stock price volatility is significantly lower than the broader market, moving at roughly 60% of the magnitude of market index swings.
Growth & Income
Revenue growth year-over-year is recorded at 9.3%, whereas earnings growth is marked as N/A, indicating that the market does not currently project a specific expansion rate for net income or that historical data is insufficient to calculate a consistent growth trajectory. The company does not distribute dividends to shareholders, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which implies that earnings are retained entirely for reinvestment into operations, debt reduction, or strategic acquisitions rather than being distributed as income to investors. The absence of a dividend payout suggests a capital allocation strategy focused on internal growth and balance sheet management, particularly given the company's high debt levels and low profit margins. Overall, the growth and income profile is characterized by top-line expansion in the double-digit percentage range coupled with a complete lack of dividend income, relying on potential capital appreciation or operational improvements to drive shareholder value.